Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
This is the complete answer, not a partial one — the list is never padded.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Daniel O'Connell | $646,354 | $0 | $412,482 | $478,338 | $305,725 | $0 | $20,668 | $1,863,567 |
| Chief Executive Officer | ||||||||
| Jim Doherty | 520,000 | 0 | 115,070 | 133,419 | 223,600 | 0 | 20,770 | 1,012,859 |
| President and Chief Development Officer | ||||||||
| Matthew Zuga | 486,993 | 0 | 123,580 | 143,429 | 172,980 | 0 | 21,807 | 948,789 |
| Chief Financial Officer and Chief Business Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Daniel O'Connell | $1,863,567 | — | — | — |
| Jim Doherty | 1,012,859 | — | — | — |
| Matthew Zuga | 948,789 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Daniel O'Connell | RSU | 267,333 | — | $564,073 |
| Daniel O'Connell | RSU | 225,400 | — | 475,594 |
| Matthew Zuga | RSU | 70,666 | — | 149,105 |
| Matthew Zuga | RSU | 66,800 | — | 140,948 |
| Jim Doherty | RSU | 62,200 | — | 131,242 |
| Daniel O'Connell | RSU | 38,000 | — | 80,180 |
| Matthew Zuga | RSU | 11,167 | — | 23,562 |
| Daniel O'Connell | Option | 9,480 | 5.19 | — |
| Daniel O'Connell | Option | 127,969 | 6.11 | — |
| Daniel O'Connell | Option | 313,542 | 4.23 | — |
| Daniel O'Connell | Option | 260,542 | 1.83 | — |
| Matthew Zuga | Option | 3,125 | 5.19 | — |
| Matthew Zuga | Option | 40,842 | 6.11 | — |
| Matthew Zuga | Option | 82,813 | 4.23 | — |
| Matthew Zuga | Option | 77,315 | 1.85 | — |
| Jim Doherty | Option | 325,542 | 3.11 | — |
| Jim Doherty | Option | 71,919 | 1.85 | — |
Compensation is designed to attract and retain individuals with superior talent, aligning interests with stockholders through equity-based awards and performance-based incentives.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | — |
| Anti-hedging | — |
| Anti-pledging | — |
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Sean StalfortIndependent · Audit · Compensation | $77,935 | $13,696 | $15,415 | — | — | $107,046 |
| Kimberlee C. DrapkinIndependent · Audit (Chair) · Compensation | 60,000 | 13,696 | 15,415 | — | — | 89,111 |
| Laura StoppelIndependent · Audit · Nominating and Corporate Governance (Chair) · Nominating/Governance (Chair) | 55,500 | 13,696 | 15,415 | — | — | 84,611 |
| George GolumbeskiIndependent · Newly elected | 10,652 | — | 72,090 | — | — | 82,742 |
| Jeffrey L. IvesIndependent · Compensation (Chair) | 50,000 | 13,696 | 15,415 | — | — | 79,111 |
| Derrell PorterIndependent · Nominating and Corporate Governance · Nominating/Governance | 44,000 | 13,696 | 15,415 | — | — | 73,111 |
| Nathan B. FountainIndependent · Nominating and Corporate Governance · Nominating/Governance | 44,000 | 13,696 | 15,415 | — | — | 73,111 |
| Daniel O'ConnellEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 10,000 / 8,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $342,087 |
| Equity awards (grant-date value) | $82,176 |
| All other compensation | $0 |
| Total cost of the board | $424,263 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Acumen Pharmaceuticals | 2025 | Daniel O'Connell | $646,354 | $412,482 | $478,338 | $305,725 | $1,863,567 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Daniel O'Connell | DEF 14A | 2026-04-23 | 0001628280-26-026870 | Section “Summary Compensation Table” · page 32. As printed: 1,863,567. Filing ↗machine: r2 · c48 · span 390272–390281 |
| 2 | Section 01, Jim Doherty | DEF 14A | 2026-04-23 | 0001628280-26-026870 | Section “Summary Compensation Table” · page 32. As printed: 1,012,859. Filing ↗machine: r6 · c48 · span 400658–400667 |
| 3 | Section 01, Matthew Zuga | DEF 14A | 2026-04-23 | 0001628280-26-026870 | Section “Summary Compensation Table” · page 32. As printed: 948,789. Filing ↗machine: r4 · c48 · span 395329–395336 |
| 4 | Section 07, pay ratio | 10-K | 2026-03-26 | 0001628280-26-021413 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 5 | Section 08, Sean Stalfort | DEF 14A | 2026-04-23 | 0001628280-26-026870 | Section “Director Compensation”. As printed: 107,046. Filing ↗machine: span 533022–533029 |
| 6 | Section 08, Kimberlee C. Drapkin | DEF 14A | 2026-04-23 | 0001628280-26-026870 | Section “Director Compensation”. As printed: 89,111. Filing ↗machine: span 523923–523929 |
| 7 | Section 08, Laura Stoppel | DEF 14A | 2026-04-23 | 0001628280-26-026870 | Section “Director Compensation”. As printed: 84,611. Filing ↗machine: span 535418–535424 |
| 8 | Section 08, George Golumbeski | DEF 14A | 2026-04-23 | 0001628280-26-026870 | Section “Director Compensation”. As printed: 82,742. Filing ↗machine: span 528169–528175 |
| 9 | Section 08, Jeffrey L. Ives | DEF 14A | 2026-04-23 | 0001628280-26-026870 | Section “Director Compensation”. As printed: 79,111. Filing ↗machine: span 529797–529803 |
| 10 | Section 08, Derrell Porter | DEF 14A | 2026-04-23 | 0001628280-26-026870 | Section “Director Compensation”. As printed: 73,111. Filing ↗machine: span 531396–531402 |
| 11 | Section 08, Nathan B. Fountain | DEF 14A | 2026-04-23 | 0001628280-26-026870 | Section “Director Compensation”. As printed: 73,111. Filing ↗machine: span 526339–526345 |
| 12 | Section 08, Daniel O'Connell | DEF 14A | 2026-04-23 | 0001628280-26-026870 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 13 | Section 09b board cost (computed) | Computed | — | computed | Cash 342,087 + equity 82,176 + all other 0 = 424,263, summed across the director compensation table rows.machine: formula: Σ = 424,263 |
| 14 | Acumen Pharmaceuticals (subject), Section 10b CEO total | DEF 14A | 2026-04-23 | 0001628280-26-026870 | CEO total compensation as printed in Acumen Pharmaceuticals's own proxy. As printed: 1,863,567. Filing ↗machine: r2 · c48 · span 390272–390281 |